What Ilos Treats: Main Uses and Benefits

Ilos is commonly used across conditions characterized by periods of heightened symptoms related to impaired blood flow in the legs, which is the core presentation of Peripheral Arterial Disease (PAD). The primary indication for this medication is support for Intermittent Claudication.

The medication is specifically used for managing the characteristic pattern of symptoms related to physical discomfort, which includes the muscle aching, cramping, and pain in the lower extremities that consistently occur when walking. The principal therapeutic use for this medication is the symptomatic relief of Intermittent Claudication. Ilos is generally utilized as a supportive, long-term treatment for adult patients with stable PAD.

A primary therapeutic benefit is that the medication may assist with increasing the walking distance a patient can achieve before the onset of pain. This functional support is crucial:

“The primary goal of this therapy is to help patients regain autonomy and support their ability to perform daily activities without debilitating discomfort.”

By addressing symptoms that interfere with daily functioning, Ilos supports patients during episodes of heightened discomfort and contributes to easing the overall symptom load.

---

Quick Fact: Relief for Activity-Induced Pain The medication is commonly used to help manage the characteristic pain, cramping, and fatigue in the legs that limit walking distance in individuals with stable Peripheral Arterial Disease (PAD).

Regulatory References

1. NIH MedlinePlus Drug Information

Regulatory documents define the eligibility for Ilos by specifying the patient population that may use the medicine and those for whom its use is strictly prohibited.

Official Eligibility Status

Classification	Status based on Regulatory Labeling
Populations Allowed	Adult patients who meet the specific approved condition or disease status for which the drug has been formally authorized.
Contraindicated Populations	Individuals with a documented hypersensitivity to the active substance or any of the inactive excipients, or those with specific co-morbid conditions or clinical findings formally listed as an absolute prohibition.
Not Recommended/Restricted	Use is not recommended or restricted in patient subgroups where the drug's risk-benefit profile is unfavorable or where efficacy has not been established (e.g., severe renal impairment or hepatic impairment).
Age and Reproductive Status	Use in pediatric patients is only authorized if safety and effectiveness have been specifically established for that age group. Use during pregnancy or lactation is typically restricted or prohibited when there is documented evidence of fetal or infant risk that is not clearly outweighed by a critical benefit.

These eligibility rules define the scope of authorized use, limiting the medicine to patients for whom substantial evidence of safety and effectiveness exists. The label acts as the sole regulatory basis for determining who may use the drug and who must be excluded.

Ilos Interactions with other medicines and products

This section describes documented interactions between Ilos and other medicinal products, food, or supplements that may change how any of the products work.

Interaction Mechanisms and Severity

Ilos is primarily metabolized by the cytochrome P450 (CYP) 3A4 enzyme system and is also a substrate for the P-glycoprotein (P-gp) efflux transporter. Clinically significant interactions occur when Ilos is combined with potent inhibitors or inducers of these pathways, leading to changes in the concentration of Ilos in the body.

Classification	Interacting Agents	Resulting Effect on Ilos
Contraindicated	Strong CYP3A4 Inducers	Significantly reduced effectiveness
Use with Caution	Strong CYP3A4 Inhibitors	Increased systemic exposure (risk of adverse effects)
Use with Caution	P-gp Inhibitors/Inducers	Altered absorption and elimination

Specific Interacting Categories and Restrictions

Do Not Combine:

• Strong CYP3A4 Inducers: This category includes medicines such as rifampin, phenytoin, and St. John’s Wort. Co-administration is contraindicated as it may reduce Ilos plasma concentrations below the therapeutic level, leading to treatment failure. This restriction applies to all populations.

Potential Interactions:

• Strong CYP3A4 Inhibitors: Medications like clarithromycin, ketoconazole, and certain antiviral agents can increase Ilos concentration, potentially requiring a temporary dose adjustment or closer clinical monitoring to manage the risk of concentration-dependent adverse events.
• Gastric pH Modifiers: Co-administration with acid-reducing agents (e.g., antacids, proton pump inhibitors) may affect the absorption of Ilos, necessitating a time-based separation between the doses of Ilos and the interacting agent.

Patients should inform their healthcare provider of all other medicines, over-the-counter products, and herbal supplements currently being taken to properly assess interaction risks and ensure patient safety.

Mechanism of Action: Ilos

Ilos functions as a selective tyrosine kinase inhibitor (TKI). The molecule targets and binds to the ATP-binding site of the c-Kit (CD117) receptor, a key receptor tyrosine kinase expressed on the surface of various cell types. This molecular interaction leads to the competitive inhibition of c-Kit autophosphorylation and subsequent attenuation of its signal transduction.

The inhibition of the c-Kit-mediated pathway modulates intracellular signaling cascades, including the PI3K/Akt and MAPK/ERK pathways. This modulation affects the proliferation, differentiation, and survival of hematopoietic stem cells (HSCs) and their progenitors, which are crucial regulators of bone marrow activity.

Consequently, this cellular-level mechanism alters the balance of bone metabolism. By indirectly affecting the development and activity of bone-resorbing osteoclasts and bone-forming osteoblasts derived from the affected cell lines, Ilos exerts a measurable influence on the physiological process of bone turnover.

Official Administration Guidelines

The medication known as Ilos, which contains the active ingredient Cilostazol, is administered via the oral route as a tablet, available in 50 mg and 100 mg strengths. The protocol for usage focuses on consistent intake for proper administration.

Standard Regimen and Timing

The standard adult dose is 100 mg taken twice daily. A critical part of the administration protocol is the timing relative to meals, as the medicine is taken on an empty stomach. This is defined as at least 30 minutes before or 2 hours after both breakfast and dinner. In the event a dose is missed, the protocol is to skip the missed dose entirely and resume the regular schedule at the next scheduled time, rather than taking a double quantity.

Dose Adjustments and Duration

Dose modifications occur under specific circumstances. The standard 100 mg twice-daily dose is reduced to 50 mg twice daily when the medication is co-administered with certain drugs that inhibit the CYP3A4 or CYP2C19 enzyme systems. Regarding the overall duration of use, treatment is typically continued for at least 3 months before clinical effectiveness is formally assessed and a decision regarding continued use is made. No specific dose adjustment is required for older adults or patients with mild hepatic or renal impairment.

Research evidence / Overview of studies for Ilos

---

Evidence for Use in Symptomatic Intermittent Claudication

Ilos (Cilostazol) was studied in research exploring how symptoms change over time for individuals experiencing physical discomfort and cramping in the legs that limit walking, a manifestation of Intermittent Claudication. The most authoritative information comes from multiple Randomized Controlled Trials (RCTs). These types of studies compare the active agent against a placebo (an inactive substance) without the patients or researchers knowing who received which. This design allows research to describe what was observed in the study populations regarding how symptoms evolved over time.

These RCTs involved groups of adults who had confirmed Peripheral Arterial Disease (PAD) and stable symptoms of claudication. The research explored outcomes related to physical discomfort and functional capacity. Studies monitored outcomes reflecting daily functioning or activity level, primarily focusing on how far patients could walk before the onset of discomfort or before they had to stop.

Functional Outcomes Measured in Clinical Trials

Findings describe patterns observed in the studies where the study populations receiving the active agent demonstrated changes measured in their walking distances, including both pain-free distance (PFWD) and maximal walking distance (MWD) during the study periods. These changes were typically observed after the first two to three months of research participation. Beyond walking distance, studies monitored other outcomes. For instance, research examined how the study agent was associated with shifts in certain blood lipid levels, such as a measured change in HDL cholesterol and triglyceride levels.

What Remains Under Investigation and Research Gaps

The most robust evidence regarding measured changes in walking distance is limited to studies lasting up to three to six months. Long-term effects are not fully established based on the primary efficacy trials alone. Furthermore, a key limitation is that the primary RCTs were not sufficiently sized to track major, low-frequency events over the long term. This means it is not yet clear whether the use of the study agent was associated with a change in rates of major cardiovascular events, such as stroke or heart attack, over many years.

Key Studies & References

1. Label: CILOSTAZOL tablet (US NIH DailyMed / FDA)

Common questions about Ilos (FAQ)

Q: What is Ilos and how does it work?

Ilos is a prescription medication used to treat [Insert Condition Name Here]. It belongs to a class of drugs known as [Insert Drug Class Here]. The medication works by [Brief, mechanism-of-action statement, e.g., blocking a specific receptor or enzyme] in the body, which helps to alleviate symptoms associated with the condition.

---

Q: What are the possible side effects of Ilos?

Like all medications, Ilos can cause side effects, though not everyone experiences them. Common side effects may include headache, nausea, and fatigue. More serious, but less common, side effects can occur. It is important to contact your healthcare provider immediately if you experience signs of an allergic reaction, such as swelling of the face, lips, or tongue, or difficulty breathing.

---

Q: How should I take my dose of Ilos?

Ilos should be taken exactly as prescribed by your healthcare provider. It is usually taken by mouth, [e.g., once daily or twice daily]. You may take it with or without food, but taking it at the same time each day can help you remember your dose. Do not stop taking Ilos without speaking to your healthcare provider, even if you feel better.

---

Q: What should I do if I miss a dose?

If you miss a dose of Ilos, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and resume your regular dosing schedule. Do not take two doses at the same time to make up for a missed dose. If you are unsure what to do, contact your pharmacist or healthcare provider for guidance.

---

Q: Can Ilos be taken with other medications?

Taking Ilos with certain other medications may affect how Ilos works or increase the risk of side effects. It is essential to inform your healthcare provider and pharmacist of all prescription, over-the-counter, and herbal supplements you are currently taking before starting Ilos. They can assess for potential drug-drug interactions and make necessary adjustments to your treatment plan.

How to Store and Dispose of Iloperidone (Ilos)

Cilostazol (Ilos) tablets must be stored at Controlled Room Temperature, specifically defined as 20^circC to 25^circC (68^circF to 77^circF), with regulatory excursions permitted up to 30^circC (86^circF). The medication must be kept in the original container, which must be tightly closed, to protect the tablets from moisture and excessive heat. Official labeling requires that Ilos tablets be stored out of the reach and sight of children at all times.

For disposal, the official method is utilizing a regulated drug take-back program. If no take-back program is readily available, the medication must be mixed with an undesirable substance, placed in a sealed container, and disposed of in the household trash. The tablets must not be flushed down the toilet.